Lipitor, Bextra counterfeiting sentence
Executive Summary
Former NuCare Pharmaceuticals CEO Christopher Lamoreaux sentenced to 21 months in federal prison and ordered to pay $115,278.54 to the company for two counts of mail fraud involving counterfeit versions of Pfizer's Lipitor and Bextra, FDA says Nov. 9. Lamoreaux was found guilty of accepting kickbacks for negotiating a contract for NuCare to purchase and repackage counterfeit and diverted drugs from Albers Medical. He was convicted in Kansas City, Mo. federal court in July following an investigation by FDA's Office of Criminal Investigation...
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.